Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Flucelvax, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 15/11/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Fluad, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 15/11/2024, Revision: 2, Status: Authorised

Advice on the influenza virus on request from the Medical Device Coordination Group

Minutes of the HMPC meeting 4-6 May 2026

PSUSA/00002798/202411

Referral: Veterinary medicinal products containing amoxicillin, amoxicillin Article 141(1)(i) procedures Under evaluation, 17/07/2026

Tavneos

Orphan designation: infliximab Treatment of Kawasaki disease, 20/05/2026 Positive